We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
+25.36%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$2.46B
AUM Growth
+$355M
Cap. Flow
+$18.4M
Cap. Flow %
0.75%
Top 10 Hldgs %
75.82%
Holding
26
New
2
Increased
7
Reduced
9
Closed
–

Top Buys

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$59.7M
2
NVAX icon
Novavax
NVAX
+$33.9M
3
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$30.4M
4
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$14M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$10.3M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$67.8M
2
CELG
Celgene Corp
CELG
+$29.8M
3
PBYI icon
Puma Biotechnology
PBYI
+$20.5M
4
ECYT
Endocyte, Inc. Common Stock
ECYT
+$12.2M
5
MDVN
MEDIVATION, INC.
MDVN
+$5.95M

Sector Composition

Rank Sector Weight
1 Healthcare 83.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$369M 14.99%
3,889,298
-330,000
-8% -$29.8M
GILD icon
2
Gilead Sciences
GILD
$165B
$298M 12.1%
2,795,596
-692,900
-20% -$67.8M
IONS icon
3
Ionis Pharmaceuticals
IONS
$9.4B
$258M 10.48%
6,636,526
-70,000
-1% -$2.48M
INCY icon
4
Incyte
INCY
$24.4B
$211M 8.58%
4,301,867
+138,077
+3% +$6.92M
VRTX icon
5
Vertex Pharmaceuticals
VRTX
$126B
$152M 6.19%
1,354,445
-50,000
-4% -$4.76M
MDVN
6
DELISTED
MEDIVATION, INC.
MDVN
$141M 5.75%
2,859,412
-140,000
-5% -$5.95M
ALXN
7
DELISTED
Alexion Pharmaceuticals
ALXN
$121M 4.9%
727,428
– –
AGIO icon
8
Agios Pharmaceuticals
AGIO
$1.93B
$116M 4.72%
1,890,521
+1,384,521
+274% +$59.7M
PBYI icon
9
Puma Biotechnology
PBYI
$454M
$114M 4.63%
476,991
-100,000
-17% -$20.5M
PCYC
10
DELISTED
PHARMACYCLICS INC
PCYC
$85.9M 3.49%
731,542
– –
REGN icon
11
Regeneron Pharmaceuticals
REGN
$80.8B
$84M 3.42%
233,000
– –
GEVA
12
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$75.2M 3.06%
1,093,476
+195,000
+22% +$14M
ALNY icon
13
Alnylam Pharmaceuticals
ALNY
$29.3B
$61M 2.48%
781,288
+160,000
+26% +$10.3M
HALO icon
14
Halozyme
HALO
$12.2B
$58.5M 2.38%
6,430,532
+583,968
+10% +$5.56M
RDUS
15
DELISTED
Radius Health, Inc.
RDUS
$57.6M 2.34%
2,745,040
– –
NBIX icon
16
Neurocrine Biosciences
NBIX
$16.6B
$48.8M 1.99%
3,116,552
+30,000
+1% +$448K
RCPT
17
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$39.5M 1.61%
+636,773
New +$30.4M
IMGN
18
DELISTED
Immunogen Inc
IMGN
$33.5M 1.36%
3,165,816
– –
NVAX icon
19
Novavax
NVAX
$1.31B
$31.3M 1.27%
+375,000
New +$33.9M
INFI
20
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$31.1M 1.27%
2,320,737
+815,000
+54% +$9.71M
CLVS
21
DELISTED
Clovis Oncology, Inc.
CLVS
$25.3M 1.03%
558,188
– –
TSRO
22
DELISTED
TESARO, Inc.
TSRO
$19M 0.77%
704,582
– –
ACHN
23
DELISTED
Achillion Pharmaceuticals
ACHN
$12.8M 0.52%
1,279,340
-500,000
-28% -$4.64M
INVA icon
24
Innoviva
INVA
$1.48B
$12.7M 0.52%
743,244
-190,000
-20% -$4.36M
ECYT
25
DELISTED
Endocyte, Inc. Common Stock
ECYT
$4.16M 0.17%
683,522
-1,780,000
-72% -$12.2M

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 10.02% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 17.19% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q3 2014 Portfolio in Review

As of Q3 2014, BB Biotech held 26 positions worth $2.46B, up 17% from $2.1B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

BB Biotech's Q3 2014 filing shows 2 new, 7 increased and 9 reduced positions. Its largest new stake was Novavax: 375,000 shares worth $31.3M. The largest sale was Gilead Sciences, an estimated $67.8M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 85% a quarter earlier.

  • BB Biotech's largest Q3 2014 buy was Novavax: 375,000 shares worth $31.3M.
  • BB Biotech added most to Agios Pharmaceuticals in Q3 2014, an estimated $59.7M increase.
  • BB Biotech's biggest Q3 2014 reduction was Gilead Sciences, cutting an estimated $67.8M.
  • BB Biotech's ten largest holdings make up 76% of its $2.46B portfolio in Q3 2014.
  • BB Biotech opened 2 new positions and closed 0 in Q3 2014.
  • BB Biotech's portfolio value rose 17% quarter-over-quarter to $2.46B.

Based on BB Biotech's 13F filing for Q3 2014, filed 13 Nov 2014.